Protalix BioTherapeutics, Inc. Total Liabilities and Equity
Protalix BioTherapeutics, Inc. (PLX) had Total Liabilities and Equity of $110.34 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-12
- 2026-06-30: Liabilities and Equity $110.34M.
- 2026-03-31: Liabilities and Equity $102.34M.
- 2025-12-31: Liabilities and Equity $82.35M.
- 2025-09-30: Liabilities and Equity $82.26M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $110.34M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $102.34M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $82.35M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $82.26M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $78.49M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $73.89M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $73.42M 10-K · filed 2026-03-18 | |
| 2024-09-30 | $61.56M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $91.54M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $89.83M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $84.43M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $87.57M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $88.42M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $66.56M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $55.79M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $56.71M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $60.64M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $68.39M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $73.67M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $83.48M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $108.20M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $102.79M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $67.93M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $72.31M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $71.71M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $82.88M 10-Q · filed 2020-06-01 | |
| 2019-12-31 | $45.39M 10-K · filed 2021-03-30 | |
| 2019-09-30 | $53.73M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $55.24M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $61.04M 10-Q · filed 2019-05-06 | |
| 2018-12-31 | $61.13M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $65.75M 10-Q · filed 2019-03-18 | $67.20M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $51.72M 10-Q · filed 2019-03-18 | |
| 2018-03-31 | $64.80M 10-Q · filed 2019-03-18 | |
| 2017-12-31 | $72.21M 10-Q · filed 2019-03-18 | |
| 2017-09-30 | $61.06M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $59.00M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $71.85M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $82.25M 10-K · filed 2018-03-06 | |
| 2016-09-30 | $70.47M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $78.86M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $87.31M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $97.25M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $59.49M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $65.95M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $72.05M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $78.36M 10-K · filed 2016-03-08 | $78.47M 10-K · filed 2015-03-12 |
| 2014-09-30 | $84.80M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $96.65M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $103.42M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $113.33M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $121.16M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $62.31M 10-Q · filed 2013-08-08 | |
| 2013-03-31 | $69.94M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $78.73M 10-K · filed 2014-03-13 | |
| 2012-09-30 | $77.38M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $84.30M 10-Q · filed 2012-08-03 | |
| 2012-03-31 | $68.46M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $51.80M 10-K · filed 2013-02-28 | |
| 2011-09-30 | $60.83M 10-Q · filed 2011-11-07 | |
| 2011-06-30 | $71.89M 10-Q · filed 2011-08-08 | |
| 2010-12-31 | $64.73M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |